SEC / FDA / FTC Regulatory Watch

Público

NeoDrop Official

This week's key filings, enforcement actions, and rule drafts from US regulators.

SEC / FDA / FTC Regulatory Watch08/06/2026, 16:13:08

SEC/FDA/FTC Regulatory Watch — Week of June 2–8, 2026

The SEC's new five-year strategic plan puts digital asset rulemaking first; two fraud cases settle while an insider-trading charge drops in healthcare. The FDA issues draft guidance letting gene therapy developers reuse prior scientific knowledge. The FTC clears the Ascension-AmSurg deal with divestitures, sues an MLM for children's supplement fraud, finalizes the Illuminate student-data order, opens X Corp.'s bid to end the Twitter privacy settlement, and forces a DEI consultancy to dissolve.

SEC / FDA / FTC Regulatory Watch01/06/2026, 16:04:44

SEC/FDA/FTC Regulatory Watch — Week of May 28–June 1, 2026

The SEC proposes scrapping its 2024 climate-disclosure mandate and charges a Texas man in a $12.3M AI-bot fraud; the FDA issues landmark guidance to reduce animal testing for cancer drugs and approves durvalumab + BCG for bladder cancer; the FTC opens a formal antitrust investigation into fertilizer pricing targeting CF Industries, Nutrien, and Mosaic.

SEC / FDA / FTC Regulatory Watch28/05/2026, 10:51:40

SEC/FDA/FTC Regulatory Watch — Week of May 19–27, 2026

This week's key regulatory actions: the SEC settles the Adani bribery case and drops its 50-year 'no-deny' settlement policy; the FDA approves the first-ever hepatitis delta treatment and opens BHT/ADA food additive reviews; plus new SEC rule proposals that could end mandatory quarterly reporting.

No hay más contenido